A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib With Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 37
- Primary Endpoint
- The percent of absolute bioavailability (F) of R406 after oral administration of fostamatinib.
Study Overview
Brief Summary
Study in healthy males to assess bioavailability of single fostamatinib with iv micro tracer dose.
Detailed Description
A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib with Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy male volunteers aged 18 to 55 years (inclusive), with a weight of at least 50 kg and a body mass index (BMI) between 18 and 30 kg/m2 (inclusive)
- •Male volunteers willing to use barrier contraception ie, condoms with spermicide, from the first day of the investigational product administration until 3 months after the last administration of the investigational product
Exclusion Criteria
- •History of any clinically significant disease or disorder
- •History or presence of GI, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
- •Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of drug
- •Volunteers who smoke more than 5 cigarettes or the equivalent in tobacco per day
- •Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis results as judged by the Investigator
Arms & Interventions
Fostamatinib 50 mg tablet
Intervention: Fostamatinib (Drug)
Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose
Intervention: Fostamatinib (Drug)
Outcomes
Primary Outcomes
The percent of absolute bioavailability (F) of R406 after oral administration of fostamatinib.
Time Frame: Up to 96 hours post dose
Total radioactivity of [14C] R406 after an intravenous infusion of [14C]R406 in terms of AUC, AUC(0-t), Cmax, t1/2λz, MRT, CL, Vz.
Time Frame: Up to 96 hours post dose
AUC-Area under the plasma concentration time curve; AUC(0-t)-Area under plasma concentration time curve from zero to time of the last measurable concentration; Cmax - max plasma concentration; t½ λz-Terminal half-life; MRT- Mean residence time; CL - Total body clearance; Vz - Volume of distribution during the terminal phase
Pharmacokinetic (PK) profile of a single oral dose of fostamatinib and a radiolabelled intravenous micro tracer dose of [14C] R406.
Time Frame: 0, 30min, 1h, 1h 30min, 1h 45min, 1h 50min, 1h 55min, 2, 2h 5min, 2h 10min, 2h 15min, 2h30min, 3, 3h 30min, 5h30min, 9h, 12h, 18h, 24h, 30h, 48h, 72h, 96h post-dose
PK Parameters: AUC, AUC (0-t), Cmax, t½ λz and MRT
Secondary Outcomes
- Safety profile in terms of vital signs (blood pressure and pulse), clinical laboratory tests, ECGs and physical examination findings.(Up to Day 12)
- Number of participants with Adverse Events.(Up to Day 12)